Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

Part of paid clinical trials in Duarte, California.

Sponsor
NeoImmuneTech
Study ID
NCT05075603
Phase
PHASE1
Status
Completed

Conditions

  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • Refractory Diffuse Large B-cell Lymphoma
  • Refractory High Grade B-Cell Lymphoma
  • Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Efineptakin alfa — DRUG
    NT-I7 is administered via an intramuscular injection after CAR-T infusion on Day 21.
  • Tisagenlecleucel — DRUG
    Administered as standard of care as described in the package insert on Day 0.
  • Axicabtagene ciloleucel — DRUG
    Administered as standard of care as described in the package insert on Day 0.
  • Lisocabtagene Maraleucel — DRUG
    Administered as standard of care as described in the package insert on Day 0.

Study Details

This is a multicenter Phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 administration following standard of care CD19 CAR T-cell therapy for eligible subjects with r/r LBCL.

Key Dates

Start date
Aug 6, 2021
Status verified
Oct 2025
Primary completion
Dec 18, 2024
Completion
Mar 12, 2025

Study Design

Enrollment
17 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: NT-I7 after CAR-T (Kymriah, Yescarta, or Breyanzi) infusion
    CAR-T infusion administered per standard of care at Day 0 followed by NT-I7 on Day 21.

Primary Outcome Measure

For Dose Escalation Phase: Incidence of adverse events (AE) [ Time Frame: 21 Days ]

Locations (4)

FacilityCityStateZIPSite coordinators
City of HopeDuarteCalifornia91010-
Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer CenterDetroitMichigan48201-
Washington University in St. LouisSt LouisMissouri63110-
Duke Cancer InstituteDurhamNorth Carolina27710-

Find similar trials in Duarte, CA

Related Studies